Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) Gross Margin (2016 - 2025)

Historic Gross Margin for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to 32.1%.

  • Arcadia Biosciences' Gross Margin fell 7500.0% to 32.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 37.81%, marking a year-over-year decrease of 119600.0%. This contributed to the annual value of 41.27% for FY2024, which is 99200.0% down from last year.
  • According to the latest figures from Q3 2025, Arcadia Biosciences' Gross Margin is 32.1%, which was down 7500.0% from 43.37% recorded in Q2 2025.
  • In the past 5 years, Arcadia Biosciences' Gross Margin registered a high of 115.49% during Q4 2022, and its lowest value of 12.95% during Q2 2021.
  • For the 5-year period, Arcadia Biosciences' Gross Margin averaged around 33.32%, with its median value being 32.86% (2024).
  • The largest annual percentage gain for Arcadia Biosciences' Gross Margin in the last 5 years was 4806200bps (2021), contrasted with its biggest fall of -606600bps (2021).
  • Arcadia Biosciences' Gross Margin (Quarter) stood at 12.7% in 2021, then skyrocketed by 809bps to 115.49% in 2022, then plummeted by -33bps to 77.09% in 2023, then crashed by -59bps to 31.99% in 2024, then grew by 0bps to 32.1% in 2025.
  • Its Gross Margin was 32.1% in Q3 2025, compared to 43.37% in Q2 2025 and 43.17% in Q1 2025.